

## Biophytis to Present at 15<sup>th</sup> International Pharma Licensing Symposium in Paris

**Paris (France), Cambridge (Massachusetts, United States)**, September 19, 2019, 7:00pm CEST - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of drug candidates for the treatment of neuromuscular diseases, announces that Stanislas Veillet, Chief Executive Officer, will present the Company and progress with its lead drug candidate, Sarconeos (BIO101), currently in a Phase 2b clinical trial for the treatment of sarcopenia, a disease of ageing characterized by a loss of muscle mass and function responsible for mobility disabilities.

The presentation will be made on Friday September 20<sup>th</sup>, 2019 at the 15<sup>th</sup> International Pharma Licensing Symposium (IPLS) held September 18-20, 2019 in Paris, France. Mr Veillet will also participate on the same day in a panel discussion along with Professor Jean Mariani, Director of the Longevity Institute, Sorbonne Université (France), who is a member of the Biophytis' Scientific Advisory Board.

### Details are as follows:

Date: **Friday, September 20<sup>th</sup>, 2019**  
Session: **D - AGEING: a New Field of Investigation & Investment**

#### Presentation

Title: *New Therapeutics for Disease of Ageing*  
Time: 10:15am CEST

#### Panel discussion

Title: *The Pathology of Ageing Challenges and Opportunities*  
Time: 11:15am CEST

\*\*\*\*

### **About Biophytis**

Biophytis is a clinical-stage biotechnology company focused on developing therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with a primary focus on neuromuscular diseases.

Biophytis' lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule, which is currently in a Phase 2b clinical trial for sarcopenia (SARA-INT) in the US and Europe. Sarconeos (BIO101) is also being developed for the treatment of Duchenne muscular dystrophy (DMD). Biophytis expects Sarconeos (BIO101) to enter the clinic for DMD in 2020.

Biophytis is headquartered in Paris, France, and has offices in Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please visit [www.biophytis.com](http://www.biophytis.com).



## Press Release

### **Disclaimer**

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to securities of Biophytis in any country. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, Biophytis undertakes no obligation to update or revise the information contained in this press release. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

### **Biophytis Investor Relations Contact**

Daniel Schneiderman, CFO  
dan.schneiderman@biophytis.com  
Tel: +1 (857) 220-9720

### **U.S. Media Contact**

LifeSci Public Relations  
Cherilyn Cecchini, M.D.  
ccecchini@lifescipublicrelations.com  
Tel: +1 (646) 876-5196

### **Europe Media Contact**

Citigate Dewe Rogerson  
Quentin Dussart / Sylvie Berrebi / Nathaniel Dahan / David Dible  
biophytis@citigatedewerogerson.com  
Tel: +33 (0)1 55 30 70 91 / +44 (0)20 76389571

Source: Biophytis